glp 1 henry meds TrimRX Avoid the dose-up penalty! 🛑

Our finding of similar incidence of non-fatal cardiovascular outcomes with GLP1-RA compared to DPP4i is in line with the recently published FLOW study that randomized people with early to mid-stage CKD to semaglutide or placebo, which reported similar incidence of non-fatal myocardial infarction and non-fatal stroke across the semaglutide and placebo treated groups, despite a significantly reduced risk of major kidney disease events and all-cause death 44

doi: 10.1007/s00592-018-1134-y 46 BenhalimaKMathiesenERPaldaniusPMMathieuC

Third Implication The third implication concerns one of the most clinically elegant mechanisms in exercise physiology, one I did not fully appreciate for years

According to the Global Burden of Disease study, in the US, between 1990 and 2021, obesity prevalence more than doubled in adults and almost tripled in adolescents

The FDA's shortage-based enforcement discretion periods for both semaglutide and tirzepatide compounding have ended, and the regulatory environment for compounded GLP-1 products continues to evolve